Peptide Comparison
AHK-Cu vs Glow
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
AHK-Cu has stronger documented evidence (Cosmetic Clinical Studies) than Glow (Anecdotal) while both occupy the copper-peptide class. When clinical-evidence tier is the deciding factor, AHK-Cu is the safer pick. Glow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| AHK-Cu | Glow | |
|---|---|---|
| Class | Copper tripeptide (cosmetic) | Three-component regenerative blend (matrikine + cytoprotective + actin-regulator) |
| Drug class | Dermatologic | Tissue Repair |
| Mechanism | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp | Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate. |
| Route | Topical | SC injection |
| Half-life | Topical (no systemic) | Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake) |
| Dosage (research) | Topical 0.01-0.1% | Typical SC protocols deliver ~250-500 mcg per component daily for 4-6 week loading cycles. Confirm per-component dose from the vial total before reconstitution |
| Evidence tier | Cosmetic Clinical Studies | Anecdotal |
| Research depth | 3 indexed | — |
| Availability | Cosmetic | Compounding Restricted |
| Reported risks | Skin irritation; theoretical copper issues | No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick AHK-Cu or Glow?
AHK-Cu has stronger documented evidence (Cosmetic Clinical Studies) than Glow (Anecdotal) while both occupy the copper-peptide class. When clinical-evidence tier is the deciding factor, AHK-Cu is the safer pick. Glow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between AHK-Cu and Glow?
AHK-Cu is classed as Copper tripeptide (cosmetic); Glow is classed as Three-component regenerative blend (matrikine + cytoprotective + actin-regulator). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Glow, Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate. Reported half-life: AHK-Cu, Topical (no systemic); Glow, Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake). Routes in published studies: AHK-Cu, Topical; Glow, SC injection.
Which has stronger evidence, AHK-Cu or Glow?
AHK-Cu has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Glow is graded Anecdotal, with 3 cited sources on its reference page.
Which is more accessible, AHK-Cu or Glow?
Neither AHK-Cu nor Glow is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Glow, Compounding Restricted.
Are AHK-Cu and Glow ever combined?
AHK-Cu and Glow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…